Found: 6
Select item for more details and to access through your institution.
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y
- By:
- Publication type:
- Article
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.
- Published in:
- British Journal of Clinical Pharmacology, 2016, v. 82, n. 6, p. 1568, doi. 10.1111/bcp.13094
- By:
- Publication type:
- Article
Development of a Highly Specific Anti-drug Antibody Assay in Support of a Nanoparticle-based Therapeutic.
- Published in:
- AAPS Journal, 2020, v. 22, n. 4, p. 1, doi. 10.1208/s12248-020-00462-z
- By:
- Publication type:
- Article
A Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 7, p. 855, doi. 10.1002/jcph.867
- By:
- Publication type:
- Article
Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 6, p. 1288, doi. 10.1111/cts.12829
- By:
- Publication type:
- Article
Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 5, p. 916, doi. 10.1111/cts.12778
- By:
- Publication type:
- Article